CPhI North America 2022 host city Philadelphia is set to become one of the world’s biggest cell and gene therapy manufacturing hubs. But it’s just one of many centers of innovation that are helping drive the US pharma and biopharma industry.
Eagle Pharmaceuticals Inc. has announced its intention to buy Arsia Therapeutics citing its formulation viscosity reduction platform as the driver for the deal.
Investing in antibody-drug conjugates (ADCs) made sense despite CMO competition and the fact few of these hybrid drugs have been approved to date says Carbogen Amcis CEO, Mark Griffiths.
Shanghai Pharmaceuticals has bought a 70 per cent stake in ingredients developer and manufacturer Changzhou Kony Pharm in a bid to boost its standing in the API market.
Researchers have called for closer monitoring of pharma manufacturing discharges after detecting endocrine disruption in fish downstream from a Sanofi plant.
Contract manufacturing organisation (CMO) Neuland Laboratories will showcase its expanded capabilities for synthetic peptide manufacture at the 22nd American Peptide Symposium to be held in San Diego, US later this week.
PolyPid claims its new polymer-lipid combination delivery tech will let pharmas set precise release characteristics for a variety of small molecule, protein and nucleic acid-base drugs.
Novasep and instrAction have partnered to develop improved methods for the production of taxane-based active pharmaceutical ingredients (API) citing growing demand for cancer treatments as key driver.
Indian API manufacturer Shasun Chemicals and Drugs turned a previous loss into profit for Q4 of this year as it seeks to make a dent in the biosimilar manufacturing sector.
Swiss biopharmaceutical firm Biopartners has got the thumbs up from
the European Commission for its biosimilar drug Valtropin, making
it only the second biogeneric drug to have been approved in Europe
after Sandoz's Omnitrope...
Arsenal Capital Partners has acquired a majority stake in Reilly
Industries for €209 million and Velsicol Chemical for an
undisclosed fee. The purchases continue a rich vein of activity for
the private equity firm, which now hold...
Cambrex has recorded a gain in the second quarter of this year,
with growth in its Bioproducts and Human Health segments. The
performances overshadow the company's troublesome BioPharma
division, indicative of a market for outsourced...
US chemicals firm Aceto has bought the German Pharma Waldhof
business from Switzerland's Roche, making its first foray into the
market for biologically-derived active pharmaceutical ingredients
(APIs).
